-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News June 7 A few days ago, the "three-child policy" has blown up the circle of friends, and the capital market is also moving after the wind.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Pharmaceutical stocks TOP20
Note: The market value is calculated based on the closing price
"The first brother of pharmaceutical stocks" hits 600 billion market value, Pien Tze Huang is closely chasing TOP5
Since the beginning of this year, five pharmaceutical stocks including Mindray Medical, WuXi AppTec, Zhifei Biotech, and Pien Tze Huang have all increased in value by more than 50 billion yuan
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
Mindray Medical: It officially landed on the A-share market in October 2018.
In 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
In 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
Pien Tze Huang: In September last year, Pien Tze Huang won the throne of "the first brother of Chinese medicine stocks"; currently, its market value has exceeded 240 billion yuan, an increase of more than 40% since the beginning of this year
.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
Kanglong Chemical, Wantai Biological.
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
At present, there are 18 pharmaceutical stocks with a value of more than 100 billion yuan.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Wantai Bio: In April last year, Wantai Biotech officially landed on the A-share market.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
Huaxi Biology: In November 2019, Huaxi Biology was listed on the Science and Technology Innovation Board.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
The 100 billion market capitalization legion may expand again!
Among the TOP20 pharmaceutical stocks, the market value of Calais exceeds 90 billion yuan, which is expected to exceed the 100 billion market value mark; in addition, the market value of Huadong Medicine has the fastest growth rate
.
.
Recently, Kailaiying issued an announcement stating that the company plans to issue H shares and be listed on the main board of the Hong Kong Stock Exchange
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
In addition, among the TOP20 pharmaceutical stocks, Huadong Pharmaceutical's market value has grown the fastest, with an increase of 77.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Medical Network News June 7 A few days ago, the "three-child policy" has blown up the circle of friends, and the capital market is also moving after the wind.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Pharmaceutical stocks TOP20
Note: The market value is calculated based on the closing price
"The first brother of pharmaceutical stocks" hits 600 billion market value, Pien Tze Huang is closely chasing TOP5
Since the beginning of this year, five pharmaceutical stocks including Mindray Medical, WuXi AppTec, Zhifei Biotech, and Pien Tze Huang have all increased in value by more than 50 billion yuan
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
Mindray Medical: It officially landed on the A-share market in October 2018.
In 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
In 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
Pien Tze Huang: In September last year, Pien Tze Huang won the throne of "the first brother of Chinese medicine stocks"; currently, its market value has exceeded 240 billion yuan, an increase of more than 40% since the beginning of this year
.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
Kanglong Chemical, Wantai Biological.
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
At present, there are 18 pharmaceutical stocks with a value of more than 100 billion yuan.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Wantai Bio: In April last year, Wantai Biotech officially landed on the A-share market.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
Huaxi Biology: In November 2019, Huaxi Biology was listed on the Science and Technology Innovation Board.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
The 100 billion market capitalization legion may expand again!
Among the TOP20 pharmaceutical stocks, the market value of Calais exceeds 90 billion yuan, which is expected to exceed the 100 billion market value mark; in addition, the market value of Huadong Medicine has the fastest growth rate
.
.
Recently, Kailaiying issued an announcement stating that the company plans to issue H shares and be listed on the main board of the Hong Kong Stock Exchange
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
In addition, among the TOP20 pharmaceutical stocks, Huadong Pharmaceutical's market value has grown the fastest, with an increase of 77.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Medical Network News June 7 A few days ago, the "three-child policy" has blown up the circle of friends, and the capital market is also moving after the wind.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Related concept stocks and other sectors have risen, drawing a successful conclusion to the May market; on June 3, the three major A-shares The index is adjusted collectively
.
In terms of pharmaceutical stocks, there are currently 18 market capitalizations with a market value of more than 100 billion yuan, and the number has reached a new high
.
Among them, Mindray Medical hit the 600 billion market capitalization mark after being listed as the “first brother of pharmaceutical stocks”, and Pien Tze Huang is closely following the TOP5
.
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
Calais is expected to exceed the market value of 100 billion yuan
.
According to data, there are only 5 pharmaceutical stocks with a market capitalization of 100 billion in 2019, and it will increase to 11 in 2020
.
Brokerage analysis pointed out that on the one hand, the pharmaceutical sector has experienced a period of low consolidation since March, and the negative impact has gradually weakened; on the other hand, the rigid demand attribute and the epidemic benefit attribute of the pharmaceutical sector continue, superimposed on the low base effect of last year, and the pharmaceutical sector in the first quarter The overall corporate performance and strong fundamentals are the main driving force for the industry's continued recovery
.
Pharmaceutical stocks TOP20
Note: The market value is calculated based on the closing price
"The first brother of pharmaceutical stocks" hits 600 billion market value, Pien Tze Huang is closely chasing TOP5
"The first brother of pharmaceutical stocks" hits 600 billion market value, Pien Tze Huang is closely chasing TOP5 Since the beginning of this year, five pharmaceutical stocks including Mindray Medical, WuXi AppTec, Zhifei Biotech, and Pien Tze Huang have all increased in value by more than 50 billion yuan
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
.
Among them, Mindray Medical hit the 600 billion market value mark; Pien Tze Huang followed the TOP5 after winning the "first brother of Chinese medicine stocks", with an increase of more than 40% since the beginning of this year
.
Mindray Medical: It officially landed on the A-share market in October 2018.
In 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
Medical equipment medical equipment medical equipmentIn 2019, its market value exceeded 200 billion yuan, and in 2020, it exceeded the 500 billion yuan mark.
In April this year, its market value surpassed Hengrui Medicine and became the “big brother of pharmaceutical stocks”.
At present, the market value is 578.
4 billion yuan, an increase of more than 10% since the beginning of this year
.
Mindray Medical stated in its investment relations activities that R&D innovation is the company's most core and basic competitiveness, based on the accumulation of capabilities in customer demand-driven and engineering transformation in the early stage
.
The company’s current technological innovation is mainly reflected in two aspects.
One is integration.
The future clinical diagnosis and treatment will be based on the perspective of the entire hospital, with multi-disciplinary integration, multi-device integration, and multi-information integration.
Mindray’s innovation direction will be based on Layout of multiple production lines, build a medical ecosystem, and welcome integration and transformation
.
The second is intelligence.
Intelligent applications have gradually become a key direction of medical device research and development.
Data collection, information sorting, and construction of high-quality clinical databases are the key foundations for intelligent clinical applications
.
Recently, Mindray Medical announced that it intends to acquire 100% of Hytest Invest Oy and its subsidiaries at a total price of approximately 545 million euros
.
It is understood that HyTest’s main business is the research, development, production, sales and antibody service of reagent raw materials such as antigens and antibodies for in vitro diagnostics.
It is one of the most important raw material suppliers in the global in vitro diagnostic industry.
At the same time, it is also Mindray Medical’s IVD raw materials.
The core supplier of the aspect
.
Pien Tze Huang: In September last year, Pien Tze Huang won the throne of "the first brother of Chinese medicine stocks"; currently, its market value has exceeded 240 billion yuan, an increase of more than 40% since the beginning of this year
.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
Cosmetics Cosmetics Cosmetics Health Products Health Products Health Products Health Food Health Food Health Food Health Food Medicine Medicine Medicine.
In recent years, Pien Tze Huang’s performance has grown rapidly.
In 2020, its revenue will exceed 6 billion yuan, and its net profit will exceed 1.
6 billion yuan, both reaching new highs
.
In the first quarter of this year, revenue was 2.
002 billion yuan, a year-on-year increase of 16.
76%; net profit was 565 million yuan, a year-on-year increase of 20.
84%
.
Pien Tze Huang said that the company has been implementing the "one core and two wings" strategy for healthy development.
On the basis of consolidating the pharmaceutical manufacturing industry, it has strengthened the two wings of cosmetics , daily chemical products, health products , and health food , and expanded the pharmaceutical distribution industry as a supplement.
After years of meticulous construction and hard work, the company has basically formed a pattern of multi-format clusters in the health field, and the product structure has been optimized
.
Kanglong Chemical, Wantai Biological.
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
.
.
7 pharmaceutical stocks have a market value of 100 billion yuan, only two on the Sci-tech Innovation Board
At present, there are 18 pharmaceutical stocks with a value of more than 100 billion yuan.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Compared with last year, 7 new ones including Kanglong Chemical, Wantai Bio, Kangsino, and Tongce Medical have been added
.
Among the 18 pharmaceutical stocks with a market value of 100 billion yuan, only Huaxi Biological and Kangsino are from the Science and Technology Innovation Board
.
Wantai Bio: In April last year, Wantai Biotech officially landed on the A-share market.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
With 26 flat boards and a 20-fold increase, it became the most eye-catching pharmaceutical stock; currently, its market value is 135.
7 billion yuan
.
According to data, Wantai Bio is a high-tech enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
It has now developed into a leading domestic and internationally renowned in vitro diagnostic reagent and vaccine research and development enterprise
.
In the first quarter of this year, revenue was 824 million yuan, a year-on-year increase of 165.
05%; net profit was 289 million yuan, a year-on-year increase of 310.
61%
.
Wantai Bio said that the revenue growth was mainly due to the increase in revenue from bivalent cervical cancer vaccines, the increase in revenue from active raw materials, and the impact of the new crown epidemic in the same period last year; the increase in net profit was mainly due to the substantial increase in vaccine and reagent revenue
.
Huaxi Biology: In November 2019, Huaxi Biology was listed on the Science and Technology Innovation Board.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
In 2020, its market value exceeded 70 billion yuan.
Since the beginning of this year, its market value has continued to soar, increasing by more than 60%
.
It is understood that Huaxi Biotechnology is a bio-enterprise in the subdivision of "hyaluronic acid development and application" in the pharmaceutical manufacturing industry.
At present, it has formed hyaluronic acid raw materials and other biologically active substances supported by microbial fermentation technology and cross-linking technology.
, The three main businesses of medical terminal products and functional skin care products cover the complete industrial chain of hyaluronic acid raw materials and related terminal products
.
A few days ago, Huaxi Biotechnology and the Tianjin Institute of Industrial Biology of the Chinese Academy of Sciences reached a strategic cooperation.
In the future, the two parties will give full play to their respective advantages in industrial resources and technological innovation, strengthen cooperation, and jointly promote the development of the National Synthetic Biotechnology Innovation Center and the Tianjin Biomanufacturing Industrial Base.
Construction and development
.
The 100 billion market capitalization legion may expand again!
The 100 billion market capitalization legion may expand again! Among the TOP20 pharmaceutical stocks, the market value of Calais exceeds 90 billion yuan, which is expected to exceed the 100 billion market value mark; in addition, the market value of Huadong Medicine has the fastest growth rate
.
.
Recently, Kailaiying issued an announcement stating that the company plans to issue H shares and be listed on the main board of the Hong Kong Stock Exchange
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
.
If the listing is successful, Calais will become another company that achieves the "A%20H" layout after WuXi AppTec and Kanglong Chemical
.
As of the close on June 3, the market value exceeded 90 billion yuan
.
In addition, among the TOP20 pharmaceutical stocks, Huadong Pharmaceutical's market value has grown the fastest, with an increase of 77.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
86% since the beginning of this year
.
On June 2, Huadong Medicine issued an announcement that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, obtained the Japanese SCOHIA Phase I clinical product SCO-094 (dual agonist of GLP-1R and GIPR targets for the treatment of type 2 Diabetes, obesity, non-alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia and so on
.
Sino-US Huadong will pay SCOHIA a down payment of US$4 million, up to a development and registration milestone of US$11 million, a sales milestone of up to US$13 million, and a tiered net sales commission fee
.
Huadong Medicine stated that the introduction of SCO-094 in this cooperation has further enriched the company’s endocrine product pipeline, in line with the company’s development strategy of transforming to internationalization and scientific research and innovation, and will further enhance the company’s competitiveness in the field of endocrine therapy, which is not yet satisfied by the domestic market.
The clinical needs of the company provide new treatment options, which will help gradually improve the company’s internationalization and scientific research innovation level, and will have a positive impact on the company’s future R&D and innovation capabilities and the introduction of international product cooperation
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
